EDGC

245620KOSDAQ자연과학 및 공학 연구개발업

62.5 / 100

Reference Date: 2026-07-24

Financial Score26.0 / 40

News Sentiment12.5 / 25

Momentum14.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

EDGC is a global bio-genomics big data company established in 2013 as a joint venture between a Korean medical institution and the U.S.-based Diagnomics, Inc. It offers key services such as NGS-based genomic analysis, personalized diagnostic tests, and liquid biopsy (OncoCatch), along with its flagship services 'YouWho' for genetic ancestry analysis and 'NICE' for non-invasive prenatal testing. In 2021, EDGC acquired a Canadian health supplement manufacturer to expand its customized health supplement business, aiming to develop integrated precision medicine solutions through genomic-based drug development.

Number of Employees

63people

Average Salary

43.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

5.92Industry Average 43.648.0Point

Half of industry avg (excellent)

PBR

—Industry Average 2.523.5Point

ROE

—Industry Average -32.093.5Point

Debt Ratio

-28.52Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼69.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲26.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -150.7% (declining, 2yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position8.0Point

Near 52w high (100%, uptrend)

Current 741Won52-week high 74152-week low 415

1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral주식등의대량보유상황보고서(약식)2026-07-10
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-06-30
Neutral[기재정정]최대주주변경2026-06-29
Neutral[기재정정]주주총회소집공고2026-06-29